Archive for the ‘Commercialization’ Category

The long slog of medical R&D and finding inspiration

Author: Elizabeth Csaszar, 03/27/17

Research and development (R&D) of a medical therapeutic is a long slog. This isn’t news to anyone working in the field. The average time to bring a new drug product to market is over a decade. Moreover, this is the timeline when everything progresses well – funding and business decisions align, manufacturing processes come together,…Read more

Improving ultrasound imaging may have applications in regenerative medicine

Author: Guest, 03/13/17

Andy Bell, a writer working with Toronto3dprinting, loves to write about different topics related to technological gadgets and gears. 3D printing is his current interest. Though ultrasound technology is commonly associated with the imaging of fetuses in the womb, its applications are much more than just imaging. The acoustic waves generated by ultrasound devices can…Read more

Right Turn: New stem cell product for ALS seeking approval in Canada

Author: Stacey Johnson, 02/24/17

This week, BrainStorm Cell Therapeutics issued a news release announcing its intent to seek early regulatory approval to distribute its Amyotrophic Lateral Sclerosis (ALS) product to patients in Canada. This news was eagerly received by patient groups in Canada and internationally. ALS, also known as Lou Gehrig’s Disease, is a progressive neuromuscular disease in which…Read more

Learning About Industry from the Insiders at Phacilitate Cell and Gene Therapy World 2017

Author: Nicole Forgione, 02/08/17

In January, I attended Phacilitate’s Cell and Gene Therapy World in Miami, Florida. At this meeting industry leaders from around the world gather to discuss manufacturing, regulation and adoption of cell and gene therapies (C&GT). This was my first industry-focused conference, and it was a great chance to learn the ropes from experienced players in…Read more

Peter Zandstra and CCRM: Making cell therapies a commercial reality

Author: Guest, 01/31/17

Dr. Rohin Iyer is currently a Development Manager at GE Healthcare / CCRM. He did his PhD in Biomedical Engineering at the University of Toronto, and has been working in the field of stem cells and tissue engineering for over 12 years. He is an avid tweeter (follow @DrRohinIyer) on cell therapies and regenerative medicine. …Read more

Can we use animals as living incubators for human tissue?

Author: Jovana Drinjakovic, 01/16/17

Markus Grompe certainly thinks so and is working hard to make it happen. A scientist and a pediatrician specializing in inborn liver diseases, Dr. Grompe has a plan for overcoming the shortage of organ donors—the key obstacle for patients for whom the liver transplant is the only hope. Based at the Oregon Health and Science…Read more

A credit card sized lab

Author: Hamideh Emrani, 12/29/16

Professor Aaron Wheeler earned his PhD from Stanford University and, after a two-year postdoc fellowship at UCLA, joined the faculty of Chemistry at the University of Toronto. He has won numerous awards and honours for his work in the field of microfluidics and is the associate editor of Lab on a Chip. Wheeler’s lab develops…Read more

Inaugural Medicine by Design Symposium – Engineering progress in regenerative medicine

Author: Nicole Forgione, 12/21/16

On November 28 local and international leaders of the regenerative medicine (RM) community gathered at the MaRS Centre in Toronto for the first ever Medicine by Design (MbD) Symposium. The event marked the first year of the MbD program at the University of Toronto (U of T). This initiative was established based on a $114…Read more

Insights from CGTW16 – Part 3: Clinical trials, health economics and regulatory affairs

Author: Guest, 12/01/16

Amin Adibi is a biomedical engineer and a research assistant at the University of British Columbia. His areas of interest include cell manufacturing and bioprocess optimization, clinical translation of cellular therapies, health outcomes and cost-effectiveness modelling. Amin has an MSc degree from University of Calgary, where he focused on developing adjuvant MSC-based therapies for brain…Read more

Insights from CGTW16 – Part 2: scale-up challenges and closed systems

Author: Guest, 11/23/16

Amin Adibi is a biomedical engineer and a research assistant at the University of British Columbia. His areas of interest include cell manufacturing and bioprocess optimization, clinical translation of cellular therapies, health outcomes and cost-effectiveness modelling. Amin has an MSc degree from University of Calgary, where he focused on developing adjuvant MSC-based therapies for brain…Read more